Non-Insulin Peptide Drugs Market

The non-insulin peptide drugs market is projected to grow from USD 61,472.6 million in 2025 to USD 184,174.1 million by 2035, advancing at a CAGR of 11.6%. GLP-1 & Dual GLP-1/GIP Agonists are expected to lead the market with a 91.8% share in 2025, while the retail & specialty pharmacies segment is anticipated to account for the largest distribution channel market share at 69.5%.